Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tokyo-172 Strain BCG With or Without Vaccine vs TICE BCG in NMIBC
NCT03091660Phase 3Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Feb 2017
- Primary completion
- Dec 2025
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of BCG Japan in non-muscle-invasive bladder cancer (NMIBC) (3 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Time to High Grade Recurrence up to 5 years. Started Feb 2017; status: active, not recruiting.
02
Drugs
BCG Japan
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03091660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03091660.